Selective inhibition of LOXL2 activity was recently investigated as a therapeutic approach for IPF [Barry-Hamilton et al., 2010; ClinicalTrials.gov NCT01769196 (Raghu et al., 2017)]. Here, LOXL2 is linked to idiopathic pulmonary fibrosis.